IMMUNO-SUPPRESSIVE EFFECT OF HUMAN ALPHA-FETOPROTEIN - A CROSS-SPECIES STUDY

被引:21
作者
CHAKRABORTY, M [1 ]
MANDAL, C [1 ]
机构
[1] INDIAN INST CHEM BIOL,CALCUTTA 700032,W BENGAL,INDIA
关键词
D O I
10.3109/08820139309063412
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Alphafetoprotein (AFP) is the major serum protein of fetal life in human and other mammalian species. The phylogenetical concervatism of AFP demonstrated by extensive immunological cross reaction between human AFP and AFP of a number of species, suggest that AFP plays a general role in the successful pregnancy of all mammalian species. The present work clearly demonstrates the antiproliferative effect of human AFP on lymphocytes, harvested from normal human donors. The inhibitory effect of human AFP is quite significant in the same dose during blastic transformations of the lymphocytes. In this study, peripheral blood mononuclear cells were induced to blastic transformations with phytohaemagglutinin (PHA-M) and the effect of AFP was quantified by the incorporation of [H-3]-thymidine into newly synthesized DNA during 24 hrs pulse. Moreover, human AFP shows similar immuno-suppressive effect to other species of lymphocytes also. In all the three species (mouse, rat and hamster) studied, a paralleism was noted in their respective percentage of thymidine incorporation values at the comparable doses. These results establish a cross species inhibitory effect of human AFP and it may be stated that this effect is directly targeted on T-helper cells and has no interaction with interleukin-2 (IL-2).
引用
收藏
页码:329 / 339
页数:11
相关论文
共 18 条
[1]  
ABELEV GI, 1968, CANCER RES, V28, P1344
[2]  
BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77
[3]   EPITOPE ANALYSIS OF THE ONCOFETAL ANTIGEN ALPHA-FETOPROTEIN USING MONOCLONAL-ANTIBODIES [J].
CHAKRABORTY, M ;
MANDAL, C ;
MANDAL, C .
MOLECULAR IMMUNOLOGY, 1991, 28 (07) :703-710
[4]   THE MURINE PLACENTA AS AN IMMUNOLOGICAL BARRIER BETWEEN THE MOTHER AND THE FETUS [J].
CHAOUAT, G ;
KOLB, JP ;
WEGMANN, TG .
IMMUNOLOGICAL REVIEWS, 1983, 75 :31-60
[5]  
GENSKENS M, 1986, J CELL PHYSL, V128, P389
[6]  
GITLIN D, 1972, CANCER RES, V32, P979
[7]  
GITLIN D, 1975, ANN NY ACAD SCI, V7, P259
[8]  
GOEKEN NE, 1977, J IMMUNOL, V119, P139
[9]  
HEAD JR, 1984, IMMUNOLOGICAL ASPECT, P133
[10]  
HUNT SV, 1986, HDB EXPT IMMUNOLOGY, V2